Alteogen

Alteogen AAQS

The The AAQS of Alteogen (196170.KQ) as of Nov 5, 2026 is 7. In the previous year, The AAQS was 7.00 — a change of 0.00% (lower).

AAQS

7

YoY

0.00%

Last updated:

Alteogen has a current AAQS of 7.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Alteogen in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Alteogen AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
7.00 KRW
Jan 1, 2019
7.00 KRW
Jan 1, 2020
7.00 KRW
Jan 1, 2021
7.00 KRW
Jan 1, 2022
7.00 KRW
Jan 1, 2023
7.00 KRW
Jan 1, 2024
7.00 KRW
Jan 1, 2025
7.00 KRW
The Alteogen AAQS history
YEARAAQSYoY
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
70.00%
7—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alteogen Stock analysis

What does Alteogen do? Alteogen, Inc. generates revenue through its biobetter business segment, developing protein pharmaceuticals and cancer therapies, and its bio similar business segment, focusing on bio similar and animal medicines. The company sells growth hormone, herceptin, humira, antibodies, and other products primarily to healthcare providers and pharmaceutical distributors. Its biobetter segment targets oncology and protein-based treatments, while the bio similar segment serves both human and animal health markets with cost-effective alternatives to branded drugs. The firm's product portfolio includes growth hormone, herceptin, and humira, which are key revenue drivers in the biopharmaceutical sector. Herceptin and humira are well-established anticancer drugs, while growth hormone addresses endocrine disorders. The company's bio similar segment offers affordable versions of these therapies, appealing to budget-conscious healthcare systems and veterinary markets. Sales are concentrated in the human and animal medicine sectors, leveraging its dual focus on biobetter and bio similar products. Alteogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alteogen stock

The AAQS of Alteogen is 7 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Alteogen since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Alteogen

All Key Metrics — Alteogen